Find your ideal API manufacturing partner in high-growth markets globally List available now!

Onmel Patent Expiration

Onmel is a drug owned by Sebela Ireland Ltd. It is protected by 4 US drug patents filed in 2013. Out of these, 1 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 03, 2028. Details of Onmel's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486456 Itraconazole compositions with improved bioavailability
Oct, 2028

(3 years from now)

Active
US8591948 Antifungal compositions with improved bioavailability
May, 2017

(7 years ago)

Expired
US6509038 Antifungal compositions with improved bioavailability
May, 2017

(7 years ago)

Expired
US7081255 Antifungal compositions with improved bioavailability
May, 2017

(7 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Onmel's patents.

Given below is the list of recent legal activities going on the following patents of Onmel.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 12 May, 2021 US8591948
Payment of Maintenance Fee, 8th Year, Large Entity 18 Dec, 2020 US8486456
Expire Patent 27 Aug, 2018 US7081255
Maintenance Fee Reminder Mailed 05 Mar, 2018 US7081255
Post Issue Communication - Certificate of Correction 30 Apr, 2014 US8486456
Record a Petition Decision of Granted to Issue Patent in Name of the Assignee 20 Mar, 2014 US8486456
Mail-Record a Petition Decision of Granted to Issue Patent in Name of the Assignee 20 Mar, 2014 US8486456
Petition Entered 20 Mar, 2014 US8486456
Post Issue Communication - Certificate of Correction Denied 12 Dec, 2013 US8486456
Patent Issue Date Used in PTA Calculation 26 Nov, 2013 US8591948


FDA has granted several exclusivities to Onmel. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Onmel, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Onmel.

Exclusivity Information

Onmel holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Onmel's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 29, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Onmel is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Onmel's family patents as well as insights into ongoing legal events on those patents.

Onmel's Family Patents

Onmel has patent protection in a total of 5 countries. It's US patent count contributes only to 33.3% of its total global patent coverage. Click below to unlock the full patent family tree for Onmel.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Onmel's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 03, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Onmel Generic API suppliers:

Itraconazole is the generic name for the brand Onmel. 13 different companies have already filed for the generic of Onmel, with Amneal Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Onmel's generic

Alternative Brands for Onmel

Onmel which is used for treating onychomycosis of the toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes., has several other brand drugs using the same active ingredient (Itraconazole). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Janssen Pharms
Sporanox
Mayne Pharma
Tolsura


Apart from brand drugs containing the same ingredient, some generics have also been filed for Itraconazole, Onmel's active ingredient. Check the complete list of approved generic manufacturers for Onmel





About Onmel

Onmel is a drug owned by Sebela Ireland Ltd. It is used for treating onychomycosis of the toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes. Onmel uses Itraconazole as an active ingredient. Onmel was launched by Sebela Ireland Ltd in 2010.

Approval Date:

Onmel was approved by FDA for market use on 29 April, 2010.

Active Ingredient:

Onmel uses Itraconazole as the active ingredient. Check out other Drugs and Companies using Itraconazole ingredient

Treatment:

Onmel is used for treating onychomycosis of the toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes.

Dosage:

Onmel is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
200MG TABLET Discontinued ORAL